4.3 Article

Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment-Elevation Myocardial Infarction

Journal

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
Volume 5, Issue 4, Pages 541-549

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCOUTCOMES.111.964379

Keywords

myocardial infarction; peripheral vascular disease; coronary diseasece; rebrovascular disorders; aged

Funding

  1. Schering-Plough Corporation
  2. Bristol-Myers Squibb/sanofi Pharmaceuticals
  3. Millennium Pharmaceuticals Inc
  4. National Institute on Aging [R01 AG025312-01A1]
  5. Amarin
  6. AstraZeneca
  7. Bristol-Myers Squibb
  8. Eisai
  9. Ethicon
  10. Medtronic
  11. Sanofi-aventis
  12. Medicines Company
  13. Merck
  14. Canyon Pharmaceuticals
  15. Heartscape
  16. Eli Lilly/Daiichi Sankyo
  17. MAQUET Cardiovascular LLC
  18. Johnson Johnson
  19. National Heart, Lung, and Blood Institute
  20. Agency for Healthcare Research and Quality and consults for Genzyme
  21. Daiichi Sankyo
  22. Datascope
  23. Eli Lilly Company
  24. Merck Co
  25. American Heart Association
  26. American College of Cardiology
  27. Society of Thoracic Surgeons and consults for Boehringer Ingelheim
  28. Roche

Ask authors/readers for more resources

Background-The impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]) on long-term cardiovascular outcomes among older patients with acute myocardial infarction has not been well studied. Methods and Results-Patients with non-ST-segment-elevation myocardial infarction aged >= 65 years from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry who survived to hospital discharge were linked to longitudinal data from the Centers for Medicare & Medicaid Services (n=34 205). All patients were presumed to have coronary artery disease (CAD) and were classified into the following 4 groups: 10.7% with prior CVD (CAD+CVD group); 11.5% with prior PAD (CAD+PAD); 3.1% with prior PAD and CVD (CAD+PAD+CVD); and 74.7% with no polyvascular disease (CAD alone). Cox proportional hazards modeling was used to examine the hazard of long-term mortality and composite of death or readmission for myocardial infarction or stroke (median follow-up, 35 months; interquartile range, 17-49 months). Compared with the CAD alone group, patients with polyvascular disease had greater comorbidities, were less likely to undergo revascularization, and received less often recommended discharge interventions. Three-year mortality rates increased with number of arterial bed involvement as follows: 33% for CAD alone, 49% for CAD+PAD, 52% for CAD+CVD, and 59% for CAD+PAD+CVD. Relative to the CAD alone group, patients with all 3 arterial beds involved had the highest risk of long-term mortality (adjusted hazard ratio [95% CI], 1.49 [1.38-1.61]; CAD+CVD, 1.38 [1.31-1.44]; CAD+PAD, 1.29 [1.23-1.35]). Similarly, the risk of long-term composite ischemic events was highest among patients in the CAD+PAD+CVD group. Conclusions-Among older patients with non-ST-segment-elevation myocardial infarction, those with polyvascular disease have substantially higher long-term risk for recurrent events or death. Future studies targeting greater adherence to secondary prevention strategies and novel therapies are needed to help to reduce long-term cardiovascular events in this vulnerable population. (Circ Cardiovasc Qual Outcomes. 2012; 5: 541-549.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available